- Keybanc Capital Markets analyst Paul Knight downgraded Azenta Inc (NASDAQ:AZTA) to Sector Weight from Overweight.
- The analyst is unimpressed with the company’s below-consensus Q2 FY23 results and 2022 acquisition of B- Medical falling below the initial guidance.
- The company reported Q2 FY23 revenues of $148.4 million missing the consensus of $161.9 million, and adjusted EPS of $(0.06), worse than the consensus of $(0.02).
- Knight sees Azenta’s FY23 guidance reduction for revenues to $645 million-$675 million (vs. around $722 million earlier) on lower revenues from B Medical and customer inventory destocking in the Consumables & Instruments division as a matter of concern.
- The analyst reduced expectations for 2023 revenues and adjusted EPS to $645.0 million (vs. $698.4 million earlier, consensus: $692.7 million) and $0.01 (from $0.40 earlier, consensus: $0.28), respectively.
- Price Action: AZTA shares are trading lower by 18.1% at $36.81 on the last check Wednesday.
Recap: Omnicell Q2 Earnings
Omnicell (NASDAQ:OMCL) reported its Q2 earnings results on Thursday, August 4, 2022 at 04:01 PM.
Here's what investors need to know about the announcement.
Earnings
Omnicell missed estimated earnings by 1.18%, reporting an EPS of $0.84 versus an estimate of $0.85.
